摘要
脑血管痉挛(cerebral vasospasm,CVS)是动脉瘤性蛛网膜下腔出血(subarachnoid hemorrhage,SAH)后的常见并发症,是致死和致残的主要原因。clazosentan为一种特异性的A型内皮素受体竞争性拮抗剂,动物实验和临床试验都证实该药可缓解SAH引发的CVS,本文综述clazosentan的研究进展。
Cerebral vasospasm(CVS) is a common complication following aneurysmal subarachnoid hemorrhage(SAH),and is a leading cause of death and disability in SAH patients.Clazosentan,a synthetic endothelin(ET) A receptor(ETA) antagonist,has been proved to be effective for SAH-induced CVS in animal experiments and clinical trials.
出处
《医学研究生学报》
CAS
2010年第3期301-304,共4页
Journal of Medical Postgraduates
基金
国家自然科学基金(30700866)